Molecular characterization of resistance to rifampicin in clinical isolates of Neisseria meningitidis.
Among 3904 meningococcal isolates collected between October 2002 and June 2007 by the French Meningococcal Reference Centre, eight (0.20%) were resistant to rifampicin (Rif-R; MIC >1 mg/L) and 27 (0.69%) were intermediate-resistant to rifampicin (Rif-I; MICs between 0.38 mg/L and 1 mg/L) according to the E-test method. The MICs determined by agar dilution were lower, eliminating the E-test intermediate category. All Rif-R isolates had mutations in the rpoB gene, resulting in substitutions at or near amino acid position 552, which were absent in non-resistant isolates. These data suggest that a rifampicin clinical breakpoint of 1.0 mg/L should be adopted for Neisseria meningitidis.
Skoczynska
A
A
Neisseria Unit, Institute Pasteur, Paris, France. skoczek@cls.edu.pl
Ruckly
C
C
Hong
E
E
Taha
M-K
MK
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D012321:DNA-Directed RNA Polymerases / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D006801:Humans; D008589:Meningococcal Infections / Q000382:microbiology*; D008826:Microbial Sensitivity Tests / Q000592:standards; D009154:Mutation; D009345:Neisseria meningitidis / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D012293:Rifampin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D012321:DNA-Directed RNA Polymerases; C105078:RNA polymerase beta subunit; D012293:Rifampin